Kymera Therapeutics Inc. (KYMR)
NASDAQ: KYMR · Biological Products, (No Diagnostic Substances) · Watertown, MA
Our rating: Neutral
Neutral reaffirmed at $126.63, moderate conviction, October 30, 2026.
Breaks if: Turns Cautious if reported collaboration revenue falls below $20 million over any rolling four quarters — signaling that milestone and partnership economics are genuinely eroding — or if a pivotal-stage program announces a primary-endpoint miss within the next twelve months. Turns Positive if revenue recovers above $60 million annually on new milestone triggers and the free-cash-flow burn narrows to better than negative $170 million within the next four quarters.
Key figures
| Market value | $9.8B |
|---|---|
| Revenue, last 12 months | $102M |
| Net income, last 12 months | −$349M |
| Free cash flow, last 12 months | −$289M |
| Price to earnings | n/a |
| Free cash flow yield | −2.9% |
| Dividend yield | 0.0% |
| Operating margin | −396.0% |
| Return on equity | −27.3% |
| Beta to the S&P 500 | 1.45 |
| Volatility, annualized | 68.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $0.00 | −100.0% | $-1.32 | −$78M |
| June 30, 2026 | $65M | 466.4% | $-0.62 | −$55M |
| March 31, 2026 | $34M | 55.5% | $-0.71 | −$89M |
| December 31, 2025 | $3M | −61.2% | $-0.98 | −$67M |
| September 30, 2025 | $3M | −26.1% | $-0.94 | −$27M |
| June 30, 2025 | $11M | −55.3% | $-0.95 | −$61M |
| March 31, 2025 | $22M | 114.8% | $-0.82 | −$80M |
| December 31, 2024 | $7M | −84.6% | $-0.89 | −$63M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.01B: Claude 45%, Gemini 60%, Mistral 35%
- Diluted earnings per share are above zero: Claude 3%, Gemini 5%, Mistral 2%
- Free cash flow for the quarter is above zero: Claude 5%, Gemini 5%, Mistral 3%
12 ledger entries and 25 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.